More than the sum of its parts: How harmonized proteomic data reveals meaning across disparate clinical cohorts
Why harmonization matters when proteomics data aren’t comparable
In high-throughput proteomics, data generated across different instruments, workflows, and cohorts can remain difficult to compare even after normalization. Harmonization addresses these study specific differences, enabling datasets to align and reveal meaningful biological signals. The the Global Neurodegeneration Proteomics Consortium (GNPC) illustrates this power by integrating 40,000 samples from 20 international groups to uncover insights not visible in isolated studies. In this webinar, you’ll learn when normalization falls short and how harmonization strengthens cross-study and longitudinal analysis.
In this webinar you’ll:
- Recognize when basic normalization falls short of making proteomic data truly comparable
- Understand how harmonization aligns datasets across plates, batches, studies, and time
- See how aligned datasets reveal biological signals that remain hidden after normalization alone
- Determine when adding harmonization can strengthen cross-study and longitudinal analyses
David Astling, PhD
David Astling is a service and support manager at Illumina. His team provides global scientific support, bioinformatics, and data consulting for SomaLogic customers— specializing in study design, data analysis, and extracting value from data. David has a PhD in Molecular and Cell Biology from the University of California at Berkeley. Prior to joining SomaLogic, David was a research associate in the bioinformatics core lab at the University of Colorado School of Medicine, collaborating on multiple next-generation sequencing projects.
Tala Khosroheidari, PhD
Tala Khosroheidari is Director of Global Service and Support at Illumina, leading worldwide scientific and technical teams that support researchers across proteomics and multiomics. She joined SomaLogic in 2022 as Senior Director of Global Scientific Engagement, where she built global capabilities in bioinformatics, technical support, and field applications. Previously, she held leadership roles at Olink Proteomics and Illumina, and served as Core Lab Director at University of California San Diego. Tala holds advanced degrees in biotechnology, bioinformatics, and molecular biology, with deep expertise in genomics, proteomics, and translating complex data into meaningful biological insight.
More than the sum of its parts: How harmonized proteomic data reveals meaning across disparate clinical cohorts
A presentation by David Astling, PhD and Tala Khosroheidari, PhD
More webinars
WebinarRethinking Neurodegeneration Through Blood-Based Biomarkers
Proteomics is reshaping how we predict, diagnose, and understand neurodegenerative diseases. In this roundtable, leading experts Tony Wyss-Coray, PhD, and Jacob Vogel, PhD, explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets using the SomaScan™ Assay. They discuss how protein signatures can reveal brain aging, predict dementia, and track changes in disease pathways over time, with moderation by Steve Williams, MD, PhD. Learn how cutting-edge proteomics is redefining what is possible in neurological research.
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.